
Protara Therapeutics, Inc. (TARA) Market Cap
Protara Therapeutics, Inc. has a market capitalization of $209.9M.
Financials based on reported quarter end 2025-12-31
Price: $5.44
โฒ 0.31 (6.04%)
Market Cap: 209.93M
NASDAQ ยท time unavailable
CEO: Jesse Shefferman
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2014-10-22
Website: https://www.protaratx.com
Protara Therapeutics, Inc. (TARA) - Company Information
Market Cap: 209.93M ยท Sector: Healthcare
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Analyst Sentiment
Based on 8 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 1 sources)
Consensus Price Target
Low
$12
Median
$12
High
$12
Average
$12
Potential Upside: 120.6%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"TARA is currently in a pre-revenue state, reflecting no revenue generated in the latest fiscal year. The company reported a net income loss of $17.31M, indicating challenges in achieving profitability. Operating cash flow was also negative at -$16.95M, accompanied by similarly negative free cash flow of -$16.97M. Notably, TARA has a solid balance sheet with total assets of $209.47M, total liabilities of $13.06M, and a strong equity position of $196.41M, showcasing a net debt situation of -$46.30M, indicating more cash than debt. The stock price is currently at $5.01, with a one-year change of 6.60%, reflecting modest appreciation, despite a year-to-date decline of 6.88%. In terms of shareholder returns, the lack of dividends and negative net income result in limited immediate returns for investors. Overall, TARA's financial position remains precarious with continued operational losses, although the balance sheet appears robust."
Revenue Growth
Pre-revenue status raises concerns about growth potential.
Profitability
Significant net loss of $17.31M indicates ongoing challenges.
Cash Flow Quality
Negative operating and free cash flow limits financial health.
Leverage & Balance Sheet
Strong equity position with low liabilities and negative net debt.
Shareholder Returns
No dividends, minimal stock appreciation restricts returns.
Analyst Sentiment & Valuation
Price target reflects some optimism, but low performance metrics.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.





